menu
    • menu

    Company profile for Iolyx Therapeutics

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Willow Birch Pharma delivers trusted, high-quality APIs nationwide with unmatched service, compliance, and competitive value.

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Iolyx Therapeutics is redefining ocular disease treatment by pioneering targeted therapies at the intersection of immunology and ophthalmology. Leveraging innovative pathways and precision tissue-specific formulations, we develop solutions that address ocular inflammation at its source. Our therapies aim to surpass current standards—offering enhanced efficacy, safety, and convenience compared to conventional steroids and imm...
    Iolyx Therapeutics is redefining ocular disease treatment by pioneering targeted therapies at the intersection of immunology and ophthalmology. Leveraging innovative pathways and precision tissue-specific formulations, we develop solutions that address ocular inflammation at its source. Our therapies aim to surpass current standards—offering enhanced efficacy, safety, and convenience compared to conventional steroids and immunosuppressants, which are limited by systemic side effects. By focusing on the root causes of autoimmune-driven eye diseases, we are advancing a new paradigm in vision care.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Iolyx TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    1325 Howard Ave, #904 Burlingame, CA 94010
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://iolyx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/iolyx-therapeutics/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Tides Asia

    Tides Asia

    Not Confirmed

    envelop Contact Supplier

    Tides Asia

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Théa Pens $280M Deal For Iolyx's Phase 3-Ready Eye Disease Drug
    Théa Pens $280M Deal For Iolyx's Phase 3-Ready Eye Disease Drug

    03 Dec 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/thea-pens-280m-deal-iolyxs-phase-3-ready-dry-eye-disease-drug

    FIERCE BIOTECH
    03 Dec 2025
    Share Share
    Iolyx Therapeutics To Present At Eyecelerator 2025 & AAO Meeting
    Iolyx Therapeutics To Present At Eyecelerator 2025 & AAO Meeting

    09 Oct 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/10/09/3164126/0/en/Iolyx-Therapeutics-Announces-Upcoming-Presentation-at-Eyecelerator-2025-and-Poster-at-the-American-Academy-of-Ophthalmology-Annual-Meeting.html

    GLOBENEWSWIRE
    09 Oct 2025
    Share Share
    Iolyx Therapeutics Announces Phase 2 Results for ILYX-002
    Iolyx Therapeutics Announces Phase 2 Results for ILYX-002

    27 May 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/05/27/3088611/0/en/Iolyx-Therapeutics-Announces-Phase-2-Results-for-ILYX-002-in-Autoimmune-Dry-Eye-Disease.html

    GLOBENEWSWIRE
    27 May 2025
    Share Share
    Iolyx Therapeutics to Present at Ophthalmology Conferences
    Iolyx Therapeutics to Present at Ophthalmology Conferences

    12 Mar 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/03/12/3041356/0/en/Iolyx-Therapeutics-to-Present-at-Multiple-Upcoming-Ophthalmology-Conferences.html

    GLOBENEWSWIRE
    12 Mar 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search